PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2039023
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2039023
Automated Patch Clamp System Market is estimated to be valued at USD 614.7 Mn in 2026 and is expected to reach USD 981.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 614.7 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.90% | 2033 Value Projection: | USD 981.6 Mn |
The techniques available for automated patch clamping are divided into three categories: the automated glass pipette-based patch clamp, the micro-fabricated planar electrode-based patch clamp, and automated TEVC on Xenopus oocytes. The use of automated patch clamp system has increased significantly to perform cardiac safety screening. For instance, automated patch clamp systems such as IonFlux Mercury HT manufactured by Fluxion Biosciences have been used for cardiac safety profiling (hERG).
Market players are focusing on launching advanced automated patch clamp systems, in order to strengthen their market presence and expand their product portfolio, which is expected to boost growth of the global automated patch clamp system market over the forecast period. For instance, in September 2020, Fluxion Biosciences launched IonFlux Mercury Ultra, a high-throughput automated patch clamp system.
Increasing research and development of therapeutic drugs and medical devices is expected to drive growth of the automated patch clamp system market over the forecast period. According to the United Nations Educational, Scientific and Cultural Organization (UNESCO), November 2016, an estimated US$ 1.7 trillion was spent on research and development for various medical applications, globally. Moreover, the U.S. Food and Drug Administration (FDA) and its Center for Drug Evaluation and Research (CDER) approved around 59 novel drugs in 2018 compared to 46 approvals of new molecule entities in 2017.
Moreover, according to the Pharma R&D Annual Review, 2019, an estimated number of drugs under pipeline in 2019 was around 16,181, while in 2018, it was around 15,267, resulting in an overall pipeline growth by 6% in 2018.
Automated Patch Clamp System Market Segmentation